Misumi Americas makes US manufacturing strategic priority, the celebrity brand ambassador rise in pharma, AI in the hospital pharmacy, and more.

BeOne Medicines is set to invest $300m in expanding its manufacturing and research operations at the Princeton West Innovation Campus in Hopewell, New Jersey, US.

Samsung Biologics has been on a steep upward growth trajectory since receiving its first licence to produce biologic drug substances in 2015.

BMS enhances its AI computing power with NVIDIA's DGX SuperPOD as big pharma race to stay competitive within the shifting global landscape.

The adult epilepsy market across the 7MM is poised to grow at a CAGR of 4.4% from $11.4bn in 2025 to $17.8bn in 2035.

GSK's newly approved ROS1-positive NSCLC drug, Jideytro will now enter a lung cancer niche dominated by Pfizer’s Lorbrena.

Lundbeck has secured fast track designation from the US FDA for its investigational treatment, Lu AH69593, to treat narcolepsy.

Affinia Therapeutics has received FDA orphan drug designation for AFTX-201, a treatment in development for BAG3-associated DCM.

Despite a lacklustre start to the year, Novartis seems to have overcome its financial slump, reporting operating profits in Q2 that exceeded analyst expectations. The Swiss drugma ...

If introduced, the 100% tariffs would apply to all generic drugs imported to the US, which make up 90% of the nation’s prescriptions.

Samsung Biologics is set to acquire PolyPeptide Group through an all-cash public tender offer valued at SFr1.46bn ($1.81bn).